4 articles
Lonza confirmed its 2026 outlook and set new mid-term targets, planning to sell its Capsules & Health Ingredients business for $3 billion to become a pure-play drug manufacturer, targeting 10% to 13%
Lonza divests capsules and health ingredients business to Lone Star Funds for CHF 2.3 billion, finalizing its shift to a pure-play CDMO model by H2 2026.
Lonza's 2025 full-year earnings increased on strong CDMO momentum but missed estimates, with further sales and margin growth expected in 2026.
Lonza confirmed its 2025 outlook following strong Q3 performance, though it anticipates a 2.5%-3.5% negative impact on sales and earnings due to a weakening US dollar. Margins are expected to remain m
ChemBrief